Maternal and Foetal Outcomes of Newly Diagnosed Chronic Myeloid Leukemia During Pregnancy and its Long-Term Impact
This study aimed to assess pregnancy, foetal, and long-term disease outcomes in female patients newly diagnosed with CML in the chronic phase (CML-CP) during pregnancy. A retrospective analysis was conducted on female CML-CP patients presenting between January 2002 and December 2022 at our institution. Inclusion criteria encompassed patients newly diagnosed with CML-CP during pregnancy. Data pertaining to pregnancy outcomes, foetal development, and disease progression were analysed through a comprehensive review of medical records. Among the female CML patients, thirteen were diagnosed with CML-CP during pregnancy. The med...
Source: Indian Journal of Hematology and Blood Transfusion - April 5, 2024 Category: Hematology Source Type: research
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia
Acta Haematol. 2024 Apr 4. doi: 10.1159/000538651. Online ahead of print.ABSTRACTPatients with chronic myeloid leukemia in chronic phase (CML-CP) can have a normal life expectancy when treated with the BCR::ABL1 tyrosine kinase inhibitors. In recent years, treatment discontinuation and treatment-free remission (TFR) emerged as the new goal of therapy in patients with CML-CP. Deep and sustained molecular remissions for more than 3 to 5 years are associated with higher chances of a successful TFR. However, although uncommon, some patients may still experience molecular or hematological relapse after treatment discontinuation...
Source: Acta Haematologica - April 4, 2024 Category: Hematology Authors: Patrice E Nasnas Elias J Jabbour Koji Sasaki Ghayas C Issa Lucia Masarova Nicholas J Short Fadi G Haddad Source Type: research
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia
Acta Haematol. 2024 Apr 4. doi: 10.1159/000538651. Online ahead of print.ABSTRACTPatients with chronic myeloid leukemia in chronic phase (CML-CP) can have a normal life expectancy when treated with the BCR::ABL1 tyrosine kinase inhibitors. In recent years, treatment discontinuation and treatment-free remission (TFR) emerged as the new goal of therapy in patients with CML-CP. Deep and sustained molecular remissions for more than 3 to 5 years are associated with higher chances of a successful TFR. However, although uncommon, some patients may still experience molecular or hematological relapse after treatment discontinuation...
Source: Acta Haematologica - April 4, 2024 Category: Hematology Authors: Patrice E Nasnas Elias J Jabbour Koji Sasaki Ghayas C Issa Lucia Masarova Nicholas J Short Fadi G Haddad Source Type: research
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia
Acta Haematol. 2024 Apr 4. doi: 10.1159/000538651. Online ahead of print.ABSTRACTPatients with chronic myeloid leukemia in chronic phase (CML-CP) can have a normal life expectancy when treated with the BCR::ABL1 tyrosine kinase inhibitors. In recent years, treatment discontinuation and treatment-free remission (TFR) emerged as the new goal of therapy in patients with CML-CP. Deep and sustained molecular remissions for more than 3 to 5 years are associated with higher chances of a successful TFR. However, although uncommon, some patients may still experience molecular or hematological relapse after treatment discontinuation...
Source: Acta Haematologica - April 4, 2024 Category: Hematology Authors: Patrice E Nasnas Elias J Jabbour Koji Sasaki Ghayas C Issa Lucia Masarova Nicholas J Short Fadi G Haddad Source Type: research
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia
Acta Haematol. 2024 Apr 4. doi: 10.1159/000538651. Online ahead of print.ABSTRACTPatients with chronic myeloid leukemia in chronic phase (CML-CP) can have a normal life expectancy when treated with the BCR::ABL1 tyrosine kinase inhibitors. In recent years, treatment discontinuation and treatment-free remission (TFR) emerged as the new goal of therapy in patients with CML-CP. Deep and sustained molecular remissions for more than 3 to 5 years are associated with higher chances of a successful TFR. However, although uncommon, some patients may still experience molecular or hematological relapse after treatment discontinuation...
Source: Acta Haematologica - April 4, 2024 Category: Hematology Authors: Patrice E Nasnas Elias J Jabbour Koji Sasaki Ghayas C Issa Lucia Masarova Nicholas J Short Fadi G Haddad Source Type: research
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia
Acta Haematol. 2024 Apr 4. doi: 10.1159/000538651. Online ahead of print.ABSTRACTPatients with chronic myeloid leukemia in chronic phase (CML-CP) can have a normal life expectancy when treated with the BCR::ABL1 tyrosine kinase inhibitors. In recent years, treatment discontinuation and treatment-free remission (TFR) emerged as the new goal of therapy in patients with CML-CP. Deep and sustained molecular remissions for more than 3 to 5 years are associated with higher chances of a successful TFR. However, although uncommon, some patients may still experience molecular or hematological relapse after treatment discontinuation...
Source: Acta Haematologica - April 4, 2024 Category: Hematology Authors: Patrice E Nasnas Elias J Jabbour Koji Sasaki Ghayas C Issa Lucia Masarova Nicholas J Short Fadi G Haddad Source Type: research
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
AbstractIn the field of chronic myeloid leukemia (CML), new strategies are needed to increase the rate of successful treatment discontinuations, a crucial goal in this disease. Anti-PD-L1 checkpoint inhibitors are a promising therapeutic approach in CML after the demonstration of an increase of these inhibitory molecules in patients with CML. A phase Ib/II (NCT04793399, registration date March 11, 2021) open-label exploratory trial has been conducted to evaluate the safety of atezolizumab, a humanized anti-PD-L1 antibody, in combination with bosutinib in patients with newly diagnosed chronic phase CML. A total of 36 patien...
Source: Annals of Hematology - April 3, 2024 Category: Hematology Source Type: research
Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells
Journal of Interferon&Cytokine Research,Volume 44, Issue 4, Page 178-189, April 2024. (Source: Journal of Interferon)
Source: Journal of Interferon - April 3, 2024 Category: Research Authors: Burcin Tezcanli Kaymaz Nurcan Gumus Besne Celik İlayda Alcitepe Cigir Biray Avci Cagdas Aktan Source Type: research
Palmoplantar Keratoderma in a Patient of Chronic Myeloid Leukemia on Dasatinib
(Source: Indian Journal of Hematology and Blood Transfusion)
Source: Indian Journal of Hematology and Blood Transfusion - April 1, 2024 Category: Hematology Source Type: research
Ponatinib-Related Vasospastic Angina
We report 3 cases of Ponatinib-related vasospastic angina, in which prophylactic administration of nitrates or calcium channel blockers was effective.PMID:38556342 | DOI:10.1536/ihj.23-355 (Source: International Heart Journal)
Source: International Heart Journal - March 31, 2024 Category: Cardiology Authors: Michiho Shindo Chinatsu Komiyama Tetsuo Yamaguchi Kosei Kageyama Hisashi Yamamoto Yo Fujimoto Naoyuki Uchida Takahide Kodama Source Type: research
